On September 24, GENSCRIPT BIO fell 3.45% in regular trading, trading at HK$39.94 per share, with turnover of HK$664 million. The pullback came after the stock surged from approximately HK$32 to an intraday high of HK$43.12 over the preceding week, significantly overshooting JPMorgan's HK$41 target price and intensifying short-term profit-taking pressure.

The recent rally was fueled by multiple catalysts, including a collaboration with Eli Lilly's AI-driven drug discovery platform Lilly TuneLab, robust CXO sector momentum, and completion of a HK$2.327 billion share placement with roughly 70% of net proceeds earmarked for expanding AIDD platform capacity. Everbright Securities noted that AI-driven protein orders are expected to sustain triple-digit percentage growth in the second half and beyond.

Notably, JPMorgan had already executed a partial exit on September 15, selling approximately 33.75 million shares at around HK$32.74 per share for a total of HK$1.105 billion, reducing its long position from 7.37% to 5.64%. The broader Life Sciences Tools sector also traded lower on the session, with peers INSILICO down 4.01%, XtalPi down 3.04%, and WuXi Biologics down 1.23%, adding sector-wide headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)